The U.S. Food and Drug Administration removed a boxed warning about increased risk of leg and foot amputations with Johnson & Johnson’s diabetes drug Invokana.

Janssen’s Invokana became the only medicine in nearly 20 years and the first diabetes medicine ever to demonstrate a reduction in progression to end-stage renal failure in T2D patients with CKD.

Johnson & Johnson is required to add new warnings to its diabetes drug Invokana about the risk of foot and leg amputations, the U.S. Food and Drug Administration said.

Derma Sciences Inc said it would stop tests on its only drug in development after an outside assessment showed the drug was unlikely to heal foot ulcers caused by diabetes. The company’s shares slumped about 25 percent premarket on Thursday. Derma Sciences, which already has drugs on the market, said it will also stop developing […]

(Reuters Health) – Diabetes affects up to 14 percent of the U.S. population – an increase from nearly 10 percent in the early 1990s – yet over a third of cases still go undiagnosed, according to a new analysis. Screening seems to be catching more cases, accounting for the general rise over two decades, the […]